Proceeds to support the advancement of three first- and best-in-class ADC programs through upcoming clinical milestones
Read more
With this capital injection, the biotechnology company covers its financial requirements to complete the preclinical development and the first clinical trial of ITR-251, a novel drug for the treatment...
Read more
The search for safer, more effective medicines increasingly depends on understanding how biological systems respond to disease, genetic variation, and therapeutic interventions at the molecular level....
Read more
A research team from the Parc Taulí Research and Innovation Institute (I3PT) is looking for adult men with fragile X syndrome to participate in a phase II clinical trial. The study aims to evaluate t...
Read more
Purification is often where development programs stall: inadequate method design, suboptimal column selection, or a poor understanding of critical impurity profiles can consume months of development t...
Read more
The collaboration combines the IIBB-CSIC’s experience in preclinical oncology models with Chemotargets’ platform for the design and generation of pharmaceuticals in order to facilitate the discove...
Read more
In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12-mon...
Read more
Regulatory expectations for pharmaceutical development have evolved considerably over the past two decades, from a compliance-driven and empirical paradigm toward a science- and risk-based framework c...
Read more
Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off
Read more
An international study involving researchers from the Hospital del Mar Research Institute reveals a key interaction between two proteins that are fundamental in tumour development
Read more
Researchers at VHIO have published an article in the journal European Journal of Cancer on the evolution of targeted therapies in early-phase clinical trials. The study shows a progressive improvement...
Read more
Oryzon Genomics a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the first patient has been enrolled in IDEAL, its Phase II study evaluating iadadems...
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
Telum Therapeutics, a biotechnology company leveraging proprietary met...
